Mar-16 -
Leukemia Group
EORTC 06031 – Gemtuzumab ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy : a randomized phase II/III trial (AML-19) of the EORTC-LG and GIMEMA-ALWP.
EORTC found that low-dose of gentuzumab ozogamicin (GO), compared with best supportive care, prolonged survival without serious adverse effects in elderly patients with acute myelogenous leukemia (AML), who were ineligible for intensive chemotherapy.